Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

Exclusion Criteria

• •Clinically significant past history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity;
• •History or presence of malignancy other than adequately treated basal cell skin cancer;
• •Clinically relevant illness within one month prior to the screening visit or at screening visit that may interfere with the conduct of this study;
• •Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C antibody;
• •A history of seizure. However, a history of febrile seizure is allowed;
• •A hospital admission or major surgery within 30 days prior to screening;
• •Participation in any other investigational drug trial within 30 days from the last dosing of other trials to screening;
• •A history of prescription drug abuse, or illicit drug use within 6 months prior to screening;
• •A history of alcohol abuse according to medical history within 6 months prior to screening;
• •A positive screen for alcohol, drugs of abuse;
• •Tobacco use within 6 months prior to screening based on subject report;
• •Subjects with hypersensitivity to lipid-lowering agents;
• •Subjects who have participated in a previous clinical study of XZK;
• •An unwillingness or inability to comply with food and beverage restrictions during study participation;
• •Donation or blood collection of more than 1 unit (approximately 450 ml) of blood (or blood products) or acute loss of blood during the 90 days prior to screening;
• •Use of prescription or over-the-counter (OTC) medications, and herbal (including St. John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at \< 3g/day is permitted until 24 hours prior to dosing).